U
CORV

UBS’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

UBS’s Portfolio CORV Stock Details CORV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$14K Sell
1,550
-9,729
-86% -$70.8K ﹤0.01% 8474
2014
Q2 		$89K Sell
11,279
-1,481
-12% -$11.2K ﹤0.01% 6075
2014
Q1 		$101K Sell
12,760
-17,293
-58% -$139K ﹤0.01% 5969
2013
Q4 		$187K Buy
30,053
+20,269
+207% +$106K ﹤0.01% 5367
2013
Q3 		$34K Buy
9,784
+7,056
+259% +$16.1K ﹤0.01% 7381
2013
Q2 		$6K Buy
+2,728
New +$5.47K ﹤0.01% 9152

Other funds holding CORV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS's CORV Position: Q3 2014 in Review

UBS reduced its Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) stake by 86% in Q3 2014, selling an estimated $70.8K and leaving 1,550 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #8474.

UBS first reported a position in CORV in Q2 2013 and has held it in 6 quarters since. The position peaked at $187K in Q4 2013. 27 funds tracked by Wall St. Rank hold CORV as of Q3 2014.

  • UBS held 1,550 shares of Correvio Pharma Corp. Ordinary Shares (Canada) worth $14K as of Q3 2014.
  • UBS sold 9,729 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q3 2014, an estimated $70.8K.
  • Correvio Pharma Corp. Ordinary Shares (Canada) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8474 holding.
  • UBS first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q2 2013 and has held it in 6 quarters since.
  • UBS's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $187K in Q4 2013.
  • 27 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.